In the black.

Way, way in the black. We’re talking profit margins on cancer drugs. Some say Big Pharma gets a bad wrap when it comes to business tactics, but ast year we learned that revenue was more than double the cost in the development of successful cancer drugs. This larger observational study of roughly 100 cancer drugs approved by the US FDA in the last three decades reports that, while median time to recover maximum costs was 5 years, billion-dollar revenues continued long after expiration of market exclusivity. After doing the math, this all translated to an astounding $15 return on every $1 investment in research and development.. TBL: More data is making it more difficult to justify the outrageous price points of oncologic pharmaceuticals. | Tay-Teo, JAMA 2019